Melbourne, Australia; 20 August 2007: Australia's adult stem cell company, Mesoblast Limited (ASX:MSB;USOTC:MBLTY), today announced that preclinical trials of its patented adult stem cells had shown that the therapy significantly protected knee cartilage against damage in osteoarthritis.
Millions of people have osteoarthritis of the knee.
More than 10 million people in the US currently suffer from osteoarthritis of the knee, making it the most common joint disease. Osteoarthritis results in loss of cartilage which cannot repair itself after injury and for which there is no effective therapy. Current treatments attempt to alleviate painful symptoms but are unable to preserve the cartilage lining the joint. Moreover, many of the currently used pharmaceutical therapies are associated with severe side-effects and can even cause death. Joint replacement is often the only option for restoring function.
You may have knee osteoarthritis some day even if you don't now. Or you'll have it in your back or hands or shoulders or hips or some combination thereof. Your parts are wearing out. You need replacement parts.
People and dogs really suffer from decaying joints. We need stem cell therapies for joint rejuvenation and repair.
With the support of the Australian Government's Commercial Ready Grant award, Mesoblast's cartilage trials evaluated the effectiveness and safety of the company's allogeneic (donor unrelated) adult stem cells to treat osteoarthritis of the knee in 48 sheep arthritic joints. The results showed that joint cartilage in osteoarthritic knees of animals receiving Mesoblast's stem cells had significantly greater thickness, reduced breakdown, and greater biomechanical strength three months after injection into the knee than did control joints receiving injections of hyaluronic acid.
The trial's principal investigator, Professor Rick Read at the Murdoch University in Western Australia, said: "We are delighted with the significant cartilage protective effects of Mesoblast's allogeneic cells in our large animal model of knee osteoarthritis, without any adverse events of the cells at all".
We need this technology to work in humans. The benefits will be enormous. We need it faster.
|Share |||Randall Parker, 2007 August 23 11:19 PM Biotech Stem Cells|